Tabula Rasa HealthCare (NASDAQ:TRHC)‘s stock had its “outperform” rating reaffirmed by equities research analysts at William Blair in a research note issued to investors on Tuesday.
Several other research firms have also commented on TRHC. Piper Jaffray Companies upped their target price on Tabula Rasa HealthCare to $43.00 and gave the company an “overweight” rating in a research note on Tuesday. Zacks Investment Research lowered Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. BidaskClub downgraded Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research report on Friday, December 15th. Citigroup started coverage on Tabula Rasa HealthCare in a research report on Thursday, January 4th. They set a “buy” rating for the company. Finally, Oppenheimer started coverage on Tabula Rasa HealthCare in a research report on Monday, December 18th. They set an “outperform” rating and a $35.00 price target for the company. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $30.67.
Tabula Rasa HealthCare (TRHC) opened at $37.80 on Tuesday. The company has a market capitalization of $652.20, a price-to-earnings ratio of -151.20, a P/E/G ratio of 3.81 and a beta of 3.60. Tabula Rasa HealthCare has a 12 month low of $11.59 and a 12 month high of $39.81. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.73 and a quick ratio of 0.66.
In other news, Director Bruce Luehrs sold 15,664 shares of the company’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $37.09, for a total value of $580,977.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Calvin H. Knowlton sold 8,000 shares of the company’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $32.75, for a total value of $262,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 295,021 shares of company stock valued at $10,167,309. 45.80% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN boosted its position in shares of Tabula Rasa HealthCare by 79.8% in the third quarter. Wells Fargo & Company MN now owns 12,768 shares of the company’s stock worth $341,000 after buying an additional 5,668 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of Tabula Rasa HealthCare in the third quarter worth about $563,000. EAM Investors LLC purchased a new stake in shares of Tabula Rasa HealthCare in the third quarter worth about $3,931,000. Vanguard Group Inc. boosted its position in shares of Tabula Rasa HealthCare by 13.4% in the second quarter. Vanguard Group Inc. now owns 236,964 shares of the company’s stock worth $3,566,000 after buying an additional 27,997 shares during the period. Finally, Quadrant Private Wealth Management LLC purchased a new stake in shares of Tabula Rasa HealthCare in the fourth quarter worth about $569,000. 53.03% of the stock is owned by institutional investors.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.